ATRCMG2 Activators
ATRCMG2 Activators are a collection of chemical compounds that facilitate the enhancement of ATRCMG2 activity through diverse signaling mechanisms. Compounds like Forskolin and IBMX raise the levels of cAMP, a secondary messenger that activates PKA, leading to phosphorylation of target proteins that may include ATRCMG2. Similarly, increased cGMP levels through the action of Sildenafil, a PDE5 inhibitor, activate PKG which can also target ATRCMG2. Epigallocatechin gallate and Curcumin offer a broader spectrum of kinase inhibition, thus relieving ATRCMG2 from negative regulatory phosphorylation, while Sphingosine-1-phosphate and Anandamide operate through G protein-coupled receptor pathways, potentially culminating in the activation of ATRCMG2. Additionally, Zinc ions may serve a structural role, engaging directly with ATRCMG2 if it possesses a zinc-binding motif, thus enhancing its functional capacity.
Further, Resveratrol's activation of sirtuins could indirectly enhance ATRCMG2 if it is part of sirtuin-regulated pathways, and nitric oxide donors such as Sodium nitroprusside may ramp up cGMP levels, activating PKG and potentially influencing ATRCMG2 activity. The action of PMA reflects another dimension of regulation, as it activates PKC, which could phosphorylate and thus activate ATRCMG2 if it is within PKC's scope of influence. Lithium ions add to this regulatory milieu by inhibiting GSK-3, potentially de-repressing ATRCMG2 activity if GSK-3 is a negative regulator of the protein. These chemicals collectively orchestrate a multifaceted enhancement of ATRCMG2, leveraging cellular signaling cascades and molecular interactions to augment the protein's activity without necessitating changes in its expression levels.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin directly stimulates adenylyl cyclase, increasing intracellular cAMP levels. Elevated cAMP activates PKA, which can phosphorylate ATRCMG2, leading to its enhanced functional activity in cell signaling processes where ATRCMG2 is a regulatory element. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which is involved in multiple signaling pathways. PKC can phosphorylate and enhance the activity of ATRCMG2 if it is a substrate or associated regulator, thus increasing ATRCMG2’s functional role in these pathways. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin acts as a calcium ionophore, elevating intracellular calcium levels. This can activate calcium-dependent kinases, such as calmodulin-dependent kinase, which may phosphorylate and enhance the activity of ATRCMG2 in calcium-regulated pathways. | ||||||
8-Bromoadenosine 3′,5′-cyclic monophosphate | 23583-48-4 | sc-217493B sc-217493 sc-217493A sc-217493C sc-217493D | 25 mg 50 mg 100 mg 250 mg 500 mg | $108.00 $169.00 $295.00 $561.00 $835.00 | 2 | |
8-Bromoadenosine 3',5'-cyclic monophosphate is a cell-permeable cAMP analog that activates PKA. PKA can then phosphorylate ATRCMG2, if it is part of the cAMP-dependent signaling pathways, leading to enhanced activity of ATRCMG2. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a known inhibitor of certain types of kinases. This inhibition can reduce negative regulatory phosphorylation events, potentially enhancing the activity of ATRCMG2 if it is regulated by such kinases within signaling pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can alter downstream AKT signaling. If ATRCMG2 operates downstream of PI3K/AKT and is negatively regulated by it, the inhibition of PI3K can lead to enhanced activity of ATRCMG2. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is an inhibitor of MEK, which is part of the MAPK/ERK pathway. If ATRCMG2 is a protein that functions downstream of this pathway and is positively influenced by its inhibition, PD 98059 can enhance the activity of ATRCMG2. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a nonspecific inhibitor of phosphodiesterases, which increases intracellular cAMP and cGMP by preventing their degradation. This can lead to the activation of PKA or PKG, potentially enhancing the activity of ATRCMG2 if it is involved in these pathways. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol is a beta-adrenergic agonist that increases cAMP levels by activating adenylyl cyclase. The resultant PKA activation can lead to phosphorylation and enhanced activity of ATRCMG2 if it is part of the beta-adrenergic pathway. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin is a JNK activator, which can lead to the phosphorylation of transcription factors and other proteins. If ATRCMG2 is a JNK substrate or is regulated by JNK-mediated signaling, anisomycin can enhance the activity of ATRCMG2. | ||||||